Skip to main content

Part of the book series: SpringerBriefs in Pharmaceutical Science & Drug Development ((BRIEFSPSDD))

  • 932 Accesses

Abstract

This chapter introduces diabetes, an ancient disease that continues to affect diverse populations in modern times and the various types of diabetes are discussed. Insulin has been traditionally used to treat the disease. However, the one significant limitation of using insulin is that an insulin overdose is the single most potent cause of life-threatening hypoglycemia. Glucagon-like Peptide-1 (GLP1) is a 30 amino acid peptide that stimulates insulin only when the blood glucose level is high, hence the risk of hypoglycemia is substantially minimized. However, the biggest problem in the therapeutic use of GLP-1 is its extremely short half-life in plasma (~2 min). In the last subsection of this chapter, the utility of prodrugs is discussed in general and how GLP-1 based prodrugs could appropriately extend the biological half life and broaden the therapeutic index of GLP.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Majumdar SK (2001) Bull Indian Inst His Med Hyderabad 31(1): 57–70

    Google Scholar 

  2. Pendergrass M (2007) Nat Endocrinol Metabol 3(1):1

    Article  Google Scholar 

  3. http://www.diabetes.org

  4. Cryer PE (2007) Nat Endocrinol Metabol 3(1):4–5

    Article  Google Scholar 

  5. Onkamo P et al (2000) Diabetologia 43(10):1334–1336

    Article  Google Scholar 

  6. Kishiyama CM, Chase H, Barker JM (2006) Rev Endocr Metab Disord 7(3):215–224

    Article  PubMed  Google Scholar 

  7. The Diabetes Control and Complications Trial Research Group (1998) Ann Intern Med 128(7):517–523

    Google Scholar 

  8. Cavaghan MK et al (2000) J Clin Investig 106:329–333

    Article  PubMed  CAS  Google Scholar 

  9. Sadikot SM Jaslok Hospital and Research Centre, Mumbai http://diabetesindia.com/

  10. United Kingdom Prospective Diabetes Study (1995) Diabetes 44:1249–1258

    Google Scholar 

  11. http://www.diabetes.org/gestational-diabetes.jsp

  12. Banting FG et al (1922) Can Med Assoc J 12:141–146

    PubMed  CAS  Google Scholar 

  13. Banting FG, Best CHJ (1922) J Lab Clin Med 7:464–472

    CAS  Google Scholar 

  14. Sanger F (1959) Science 129(3359):1340–1344

    Article  PubMed  CAS  Google Scholar 

  15. Lepore M et al (2000) Diabetes 49(12):2142–2148

    Article  PubMed  CAS  Google Scholar 

  16. De León DD, Stanley CA (2007) Nat Clin Pract Endocrinol Metab 3:57–68

    Article  PubMed  Google Scholar 

  17. The Diabetes Control and Complications Trial Research Group (1993) The. N Engl J Med 329(14):977–986

    Article  Google Scholar 

  18. Nicholas GA, Gomez-Caminero A (2007) Diab, Obes Metab 9(1):96–102

    Article  Google Scholar 

  19. Johnston LW, Weinstock RS (2006) Mayo Clin Proc 81(12):1615–1620

    Article  Google Scholar 

  20. Nauck MA et al (2002) J Clin Endocrinol & Metab 87(3):1239–1246

    Article  CAS  Google Scholar 

  21. Schmidt WE, Siegel EG, Creutzfeldt W (1985) Diabetologia 28(9):704–707

    Article  PubMed  CAS  Google Scholar 

  22. Green BD et al (2003) Biol Chem 384:1543–1551

    Article  PubMed  CAS  Google Scholar 

  23. Holst JJ (1999) Trends Endocrinol Metab 10:229–234

    Article  PubMed  CAS  Google Scholar 

  24. McCormack JG (2006) Biochem Soc Trans 34:238–242

    Article  PubMed  CAS  Google Scholar 

  25. Orskov C et al (1996) World J Gastroenterol 31:665–670

    CAS  Google Scholar 

  26. Daniel J et al (2006) Lancet 368(9548):1696–1705

    Article  Google Scholar 

  27. Giorgino F et al (2006) Diab Res Clin Pract 74(2):S152–S155

    Article  CAS  Google Scholar 

  28. Butler AE et al (2003) Diabetes 52:102–110

    Article  PubMed  CAS  Google Scholar 

  29. Nauck M et al (1986) Diabetologia 29:46–52

    Article  PubMed  CAS  Google Scholar 

  30. Drucker DJ et al (1987) Proc Natl Acad Sci 84:3434–3438

    Article  PubMed  CAS  Google Scholar 

  31. Holz GG et al (1999) J Biol Chem 274:14147–14156

    Article  PubMed  CAS  Google Scholar 

  32. Gromada J et al (1998) Pflugers Arch 435:583–594

    Article  PubMed  CAS  Google Scholar 

  33. Weir GC et al (1989) Diabetes 38:338–342

    Article  PubMed  CAS  Google Scholar 

  34. Hui H et al (2005) Diab/Metab Res Rev 21:313–331

    Article  CAS  Google Scholar 

  35. Rabenhoj L et al (1994) Diabetes 43(4):535–539

    Article  PubMed  Google Scholar 

  36. Adelhorst K et al (1994) J Biol Chem 269(9):6275–6278

    PubMed  CAS  Google Scholar 

  37. Larsen J et al (2001) Diab Care 24:1416–1421

    Article  CAS  Google Scholar 

  38. Ørskov C, Wettergren A, Holst JJ (1993) Diabetes 42:658–661

    Article  PubMed  Google Scholar 

  39. Deacon CF et al (1995) J Clin Endocrinol Metab 80:952–957

    Article  PubMed  CAS  Google Scholar 

  40. Knudsen LB, Pridal L (1996) Eur J Pharmacol 318:429–435

    Article  PubMed  CAS  Google Scholar 

  41. Holst JJ, Deacon CF (1998) Diabetes 47(11):1663–1670

    Article  PubMed  CAS  Google Scholar 

  42. Åhren B et al (2004) J Clin Endocrinol Metab 89:2078–2084

    Article  PubMed  Google Scholar 

  43. Stuart AR, Gulve EA, Minghan W (2004) Chem Rev 104(3):1255–1282

    Article  Google Scholar 

  44. Thorens B et al (1993) Diabetes 42(11):1678–1682

    Article  PubMed  CAS  Google Scholar 

  45. Eng J et al (1992) J Biol Chem 267(11):7402–7405

    PubMed  CAS  Google Scholar 

  46. Kolterman OG et al (2005) Am J Health Syst Pharm 62:173–181

    PubMed  CAS  Google Scholar 

  47. Kendall DM et al (2005) Diab Care 28:1083–1091

    Article  CAS  Google Scholar 

  48. Knudsen LB et al (2000) J Med Chem 43:1664–1669

    Article  PubMed  CAS  Google Scholar 

  49. Bjerre KL et al (2005) Diabetes 52(1):321–322

    Google Scholar 

  50. Deacon CF (2004) Diabetes 53:2181–2189

    Article  PubMed  CAS  Google Scholar 

  51. IUPAC Pure & Applied Chemistry (1998) 70(5):1129–1143

    Google Scholar 

  52. Albert A (1958) Nature 182:421–423

    Article  PubMed  CAS  Google Scholar 

  53. Jiunn HL, Lu AYH (1997) Pharmacology Rev 49:403–449

    Google Scholar 

  54. Stañczak A, Ferra A (2006) Pharmacol Rep 58:599–613

    PubMed  Google Scholar 

  55. Beaumont K et al (2003) Curr Drug Metab 4:461–485

    Article  PubMed  CAS  Google Scholar 

  56. Humphrey MJ, Ringrose PS (1986) Drug Metab Rev 17:283–310

    Article  PubMed  CAS  Google Scholar 

  57. Saffran M et al (1988) J Pharm Sci 77:33–38

    Article  PubMed  CAS  Google Scholar 

  58. Lee SH et al (2005) Bioconjug Chem 16:377–382

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Arnab De .

Rights and permissions

Reprints and permissions

Copyright information

© 2013 The Author(s)

About this chapter

Cite this chapter

De, A. (2013). Introduction. In: Application of Peptide-Based Prodrug Chemistry in Drug Development. SpringerBriefs in Pharmaceutical Science & Drug Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4875-4_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-4875-4_1

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-4874-7

  • Online ISBN: 978-1-4614-4875-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics